Would you accept 96.4% on cagrilintide from HJ without a content assay?

What I am working with: 96.4% · cagrilintide · HJ.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

How would you structure this, and what thresholds would you set in advance?

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 1 Nov 2025 by Dr_Colm_Fitzhenry — tightened the wording; no substantive change

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Concretely, mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

Compare purity within a single laboratory on the same method, never across laboratories.

Concretely, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

If you are ranking vendors, specify a method and have all samples tested at the same place.

On the detail: the short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 2 Sept 2025 by sian_llewellyn — added the citation requested in comments